PAR2026-04-012026-06-30PAR2026-04-012026-06-30in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares000000PARNOTLISTEDINE04LG01015PAR DRUGS AND CHEMICALS LIMITEDMain BoardEquity2026-04-012027-03-312026-08-082026-07-31INRLakhsQuarterlyFirst quarterSingle segmentThe Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on “Operating Segments”. Accordingly, there are no separate reportable segments as per Ind AS - 108.2026-08-0815:30:002026-08-0817:10:00Not applicablefalsefalseAs there is no any outstanding default on loans and debt securities as on 30.06.2026.2026-04-012026-06-30UnauditedStandalone312805000935300032215800012835000009089000168920002140009642000946700002588570006330100006330100016174000016174000047127000000047127000047127000123046000103.833.83003.833.831. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time. <br /> <br /> 2. The above quarterly and year to date financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 08th August, 2026. <br /> <br /> 3. The Statutory auditors of the company have carried out Limited Review of the above quarterly financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. <br /> <br /> 4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS. <br /> <br /> 5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures. <br /> <br /> 6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on “Operating Segments”. Accordingly, there are no separate reportable segments as per Ind AS - 108. <br /> <br /> 7. The Company does not have any subsidiary, associates or joint venture as on 30th June, 2026; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company. <br /> <br /> 8. The above unaudited financial results of the Company are available on the Company’s website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company’s shares are listed. <br /> <br /> 9. The Status of investors complaints are as follows: <br /> I. Pending at the beginning of the quarter - 0 <br /> II. Received during the quarter - 0 <br /> III. Disposed-off during the quarter - 0 <br /> IV. Remaining unresolved at the end of the quarter - 0 <br /> <br /> Other expenses94670000